HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives
Executive Summary
The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month.
You may also be interested in...
AMA Shares OTC Birth Control Diagnosis With FDA
American College of Obstetricians and Gynecologists proposed amending existing AMA policy in anticipation of Perrigo’s HRA business submitting NDA to FDA for OTC switch of progestin-only daily oral contraceptive the end of 2022.
Likely Limits On Reproductive Rights Drive Democrats’ Urgency For OTC Oral Contraceptive
Sponsors in both chambers amplify the FDA’s role announcing the legislation, saying the bills intend to “maintain the FDA’s sole authority to determine the safety and efficacy of drugs and make them available over-the-counter without a prescription.”
UK Looks To Switch Overactive Bladder Treatment
Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.